NCI Stock Recent News

Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations

SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of the Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in methylthioadenosine phosphorylase (MTAP)-deletion urothelial and non-small cell lung cancer (NSCLC) patients at the 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place on October 23 to 25, 2024, in Barcelona, Spain.

HONG KONG, July 09, 2024 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), announced that, on July 8, 2024, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that based on the closing bid price of the Company for the period from May 21, 2024 to July 5, 2024, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

Neo-Concept (NASDAQ: NCI ) stock is up on Thursday alongside heavy pre-market trading for the apparel solutions company's shares this morning. This has more than 13 million shares of the company's stock changing hands as of this writing.

HONG KONG, May 29, 2024 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced a game-changing acquisition. The company has signed an Asset Purchase Agreement (“APA”) to acquire the intellectual property (“IP) and R&D capabilities of its affiliated company, Neo-Concept (Holdings) Company Limited (“NCH”).

HONG KONG, May 22, 2024 (GLOBE NEWSWIRE) --  Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced that its wholly-owned subsidiary Neo-Concept UK Limited (“NCUK”) had entered into a framework collaboration agreement (the "Collaboration Agreement") with Reiss Limited (“REISS”) to produce a range of co-branded “REISS x Les100Ciels” products.

HONG KONG, May 21, 2024 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced its expansion plan of UAE and GCC retail markets through the signing of a Memorandum of Understanding (“MOU”) with Liwa Trading Enterprises LLC (“Liwa”), a prominent retail group headquartered in the United Arab Emirates (“UAE”), to establish a joint venture company (“JV”) in the UAE.

Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Index was up 23.5% year-to-date, while the S&P 500 was up 14.0%. Renaissance Capital's IPO ETF tracks Renaissance IPO Index, and top ETF holdings include Palantir Technologies and Kenvue.

Neo-Concept International Group Holdings Limited has filed for a micro-IPO to raise $9 million. The company offers apparel design, manufacturing, and logistics management services. Neo-Concept's revenue has declined, cash burn is high, and valuation expectations are excessive.